News

Partnership to discover GPCR-modulating antibodies

Abalone Bio and Pfizer Launch Research Collaboration to Discover GPCR-Modulating Antibodies

What to know about new GLP-1 weight loss pill

Abalone Bio & Sihuan Pharmaceutical Launch Collaboration to Develop a Novel Obesity Drug

Reimagining Antibody Drug Discovery with AI

Abalone Bio Talks Opportunities for GPCR Targets

Novel Antibody Technologies Expand Potential Cancer Applications

Unlocking the Pharmacological Potential of Antibodies

Functional Antibody Screening with Abalone Bio's Richard Yu, Ph.D

Abalone Bio and Mount Sinai Publish Preclinical Data on World's First CB2 Antibody Agonists

Abalone Bio and University of Pennsylvania Announce Collaboration to Develop Next-Generation Obesity Drugs

CB2 Specific Antibody Agonists for Treatment of Peripheral Neuropathy and Liver Fibrosis

‍

Engaging Hard-To-Target Receptors with Antibodies That Activate

Partners aim to develop new class of obesity therapeutics

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

Paving the road to functionally active antibody drugs

Bay Area lab utilizes AI in search for next effective weight loss drug

East Bay company aims to tame a shrew to make better GLP-1 weight-loss drugs

GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space

Interview with Richard Yu, PhD Co-Founder & CEO, Abalone Bio

The promise and challenges of functionally active GPCR antibody drugs

FAST: Enabling the rapid discovery and creation of GPCR agonist antibodies